"Drug"

The results of a new study recently showed that Olutasidenib monotherapy in patients with relapsed/refractory acute myeloid leukaemia carrying the IDH1 mutation elicited high rates of complete remission with manageable toxicity.

Recently, the US FDA has granted orphan drug status to two new therapeutics in a row. One is a small molecule inhibitor, PCLX-001, for the treatment of acute myeloid leukaemia; the other is a T-cell therapy, ET140203, for the treatment of hepatoblastoma. Both therapies are currently in relevant trials.

The results of a new study show that Ubamatamab, a bispecific antibody drug, has shown excellent results and a good safety profile in patients with ovarian cancer.

Eisai and Biogen have partnered to develop Leqembi and have priced it at $26,500 per year.

Pancreatic cancer is known to be a highly fatal and incurable type of cancer known as the "king of cancers". Currently, the only possible cure for pancreatic cancer is the complete surgical removal of the tumour tissue. Once the cancer has spread beyond the pancreatic organ, the patient's treatment options are very limited.

On November 4, 2022, the U.S. FDA has approved the marketing of mivituximab soratansine (Elahere), a cutting-edge antibody-coupled drug targeting folate receptor alpha (FRα), for the treatment of adult patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three systemic treatment regimens and are folate receptor alpha (FRα)-positive and platinum-resistant.

Recently, a study for the treatment of advanced EGFR-mutated and c-MET-positive lung cancer showed good results with the cutting-edge ADC drug teliso-V in combination with the EGFR generation-targeted drug troche (i.e. erlotinib).

Nectin-4 is an important target that has been shown to be available as a treatment for locally advanced and advanced bladder cancer. Based on this, Padcev (enfortumab-vedotin-ejfv), the first ADC drug (antibody-coupled drug) for uroepithelial carcinoma, has also received accelerated FDA approval for the treatment of locally advanced or advanced bladder cancer in patients who have previously received immune checkpoint inhibitors (PD-L1, PD-1) and platinum-containing chemotherapy before surgery (neoadjuvant therapy) or after surgery (adjuvant therapy). Adult patients with advanced or late-stage uroepithelial carcinoma (a common type of bladder cancer).

A new study has found that Istradefylline, a drug already approved to treat Parkinson's disease, not only reduces the toxicity associated with the chemotherapy drug cisplatin, but also boosts its cancer-fighting power, promising a potential treatment to reduce the side effects of chemotherapy.

Recently, the frontier drug INT230-6 showed good tumour killing effects in the treatment of soft tissue sarcoma in the single arm phase 1/2 open-label clinical trial IT-01 (NCT03058289), and the drug showed good responses whether injected inside the tumour alone or in combination with the CTLA-4 immune checkpoint inhibitor ipilimumab.